Xeris Pharmaceuticals | Les Charges D'Exploitation



Operating Expenses Changement Date
Adcock Ingram Holdings ZAR 4.23B 196.72M 2024-12
Celltrion KRW 718.99B 24.68B 2025-06
Cspc Pharmaceutical CNY 5.22B 248.9M 2025-03
Dianthus Therapeutics USD 35.12M 1.88M 2025-06
Divis Laboratories Ltd 17.93B 130M 2025-06
Eli Lilly USD 8.54B 1.22B 2025-06
Kangmei Pharma CNY 1.25B 35.75M 2025-06
Knight Therapeutics CAD 89.06M 2.02M 2024-09
Laboratorios Farma EUR 132.33M 179.02M 2025-06
Malin Corporation EUR 1.1M 400K 2024-12
Medical Developments International AUD 19.8M 9.46M 2024-12
Neuren Pharmaceuticals AUD 17.41M 2.86M 2024-12
Organigram Holdings CAD 72.9M 18.86M 2025-06
Pacira USD 170.87M 3.93M 2025-06
Perrigo USD 1B 36.2M 2025-06
Pharma Mar EUR 32.29M 9.66M 2025-06
Qiagen NV USD 397.57M 39.27M 2025-06
Sartorius EUR 722.5M 23.1M 2025-06
Sino Biopharmaceutical CNY 11.66B 352.34M 2024-12
Supernus Pharmaceuticals USD 153.31M 892K 2025-06
Tilray USD 253.17M 16.55M 2024-11
Zz Pientze Pharmaceu 1.68B 272.39M 2025-06


Xeris Pharmaceuticals Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Sep 2025.